These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28118050)

  • 1. Administration of Biosimilar Insulin Analogs: Role of Devices.
    Heinemann L; Fritz I; Khatami H; Edelman SV
    Diabetes Technol Ther; 2017 Feb; 19(2):79-84. PubMed ID: 28118050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Practical aspects in the use of biosimilar insulins].
    Krämer I; Blüher M; Kuhlmann MK; Heinemann L
    Dtsch Med Wochenschr; 2016 Oct; 141(21):1565-1568. PubMed ID: 27750344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar insulins are coming: what they are, what you need to know.
    Edelman S; Polonsky WH; Parkin CG
    Curr Med Res Opin; 2014 Nov; 30(11):2217-22. PubMed ID: 25105307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens.
    Brunton S
    Diabetes Technol Ther; 2008 Aug; 10(4):247-56. PubMed ID: 18715198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar products are not bioidentical.
    Garber AJ
    J Diabetes; 2015 Mar; 7(2):153-4. PubMed ID: 25395269
    [No Abstract]   [Full Text] [Related]  

  • 6. Insulin devices: addressing barriers to insulin therapy with the ideal pen.
    Spollett G
    Diabetes Educ; 2008; 34(6):957-60, 963, 967. PubMed ID: 19075079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar Insulin and Costs: What Can We Expect?
    Heinemann L
    J Diabetes Sci Technol; 2015 Sep; 10(2):457-62. PubMed ID: 26350722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study.
    Haak T; Edelman S; Walter C; Lecointre B; Spollett G
    Clin Ther; 2007 Apr; 29(4):650-60. PubMed ID: 17617288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar insulins: guidance for data interpretation by clinicians and users.
    Heinemann L; Home PD; Hompesch M
    Diabetes Obes Metab; 2015 Oct; 17(10):911-8. PubMed ID: 25974131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin delivery devices--pumps and pens.
    Hirsch IB
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S115-6. PubMed ID: 20515300
    [No Abstract]   [Full Text] [Related]  

  • 11. The future of basal insulin.
    Shah VN; Moser EG; Blau A; Dhingra M; Garg SK
    Diabetes Technol Ther; 2013 Sep; 15(9):727-32. PubMed ID: 23965036
    [No Abstract]   [Full Text] [Related]  

  • 12. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization.
    Davis EM; Christensen CM; Nystrom KK; Foral PA; Destache C
    Am J Health Syst Pharm; 2008 Jul; 65(14):1347-57. PubMed ID: 18593681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, prevalence, and trend analysis of the use of insulin delivery systems in the United States (2005 to 2011).
    Perez-Nieves M; Jiang D; Eby E
    Curr Med Res Opin; 2015 May; 31(5):891-9. PubMed ID: 25710707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of biosimilar insulins in Europe.
    Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C
    Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nurse satisfaction using insulin pens in hospitalized patients.
    Davis EM; Bebee A; Crawford L; Destache C
    Diabetes Educ; 2009; 35(5):799-809. PubMed ID: 19633151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of diabetes insulin delivery devices.
    Selam JL
    J Diabetes Sci Technol; 2010 May; 4(3):505-13. PubMed ID: 20513314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of insulin delivery pen devices.
    Kroon L
    J Am Pharm Assoc (2003); 2009; 49(5):e118-31. PubMed ID: 19692314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence.
    Asche CV; Shane-McWhorter L; Raparla S
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S101-8. PubMed ID: 20515297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAR342434 - an insulin biosimilar for the treatment of type II diabetes.
    Hu J; Wang M; Zhao Y
    Expert Opin Biol Ther; 2018 Nov; 18(11):1107-1112. PubMed ID: 30295083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.
    Tieu C; Lucas EJ; DePaola M; Rosman L; Alexander GC
    PLoS One; 2018; 13(4):e0195012. PubMed ID: 29668697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.